Ingria Pratama Capitalindo Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Ingria Pratama Capitalindo Tbk. trades at Rp164 (market cap 1.23T, 3.55M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Ingria Pratama Capitalindo Tbk. is far larger — about 11.8× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| GRIA | SCPI | |
|---|---|---|
Market Cap | 1.23T | 104.4B |
Volume | 3.55M | — |
Lot | 35.52K | — |
Turnover | 569.66M | — |
Average Price | 160.38 | — |
Value | 569.66M | — |
Indicative Equilibrium Price | 164 | — |
Indicative Equilibrium Volume | 65 | — |
Trailing returns across standard periods
Latest headlines on both assets
PT Ingria Pratama Capitalindo Tbk (the “Company”) was established based on Notarial Deed No. 04 dated 8 May 2013 of Euis Widari, S.H. The Company commenced its operationalactivity with purchases of land in 2017.
Read more on GRIA →PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →